MarketCap
Arbutus Biopharma Corporation ABUS
$ 3.8
1.6%
Facebook
X
Telegram
Arbutus Biopharma Corporation ROCE Ratio | ABUS
Annual ROCE Ratio Arbutus Biopharma Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -43.06 | -65.74 | -64.06 | -40.27 | -38.04 | -44.9 | -73.02 | -32.39 | -31.52 | -37.8 | -7.65 | -33.65 | -20.53 | 80.85 | -150.45 | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 80.85 | -150.45 | -40.15 |
Quarterly ROCE Ratio Arbutus Biopharma Corporation
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 43.18 | 44.55 | 48.27 | -40.15 | -46.18 | -54.47 | -71.68 | -60.24 | -65.26 | -63.43 | -59.8 | -55.39 | -52.25 | -46.54 | -42.05 | -36.93 | -33.82 | -35.55 | -42.7 | -48.57 | -50.59 | -51.07 | -50.73 | -52.83 | -53.45 | -125.05 | -121.89 | -118.13 | -112.54 | -42.55 | -39.62 | -37.13 | -56.4 | -48.04 | -47.74 | -47.77 | -117.72 | -115.9 | -145.38 | -141.15 | -45.8 | -50.26 | -14.67 | -14.14 | -23.44 | -21.72 | -27.96 | -30.76 | -23.9 | -23.59 | -20.63 | -20.53 | -6.17 | -5.19 | -5.06 | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 48.27 | -145.38 | -47.79 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Replimune Group
REPL
|
-116.69 | $ 23.3 | 4.67 % | $ 2.16 B |  USA |
 |
Фармсинтез
LIFE
|
-4.03 | - | - | - |  Russia |
 |
Royalty Pharma plc
RPRX
|
8.21 | $ 69.47 | 1.02 % | $ 29.9 B | USA |
 |
Revolution Medicines
RVMD
|
-57.28 | $ 193.0 | -3.57 % | $ 36.7 B | USA |
 |
Rhythm Pharmaceuticals
RYTM
|
-78.92 | $ 113.99 | 0.04 % | $ 7.41 B | USA |
 |
Codiak BioSciences
CDAK
|
-129.99 | - | -55.98 % | $ 2.15 M | USA |
 |
Sana Biotechnology
SANA
|
-74.02 | $ 2.43 | -1.42 % | $ 615 M | USA |
 |
Sol-Gel Technologies Ltd.
SLGL
|
-31.74 | $ 61.81 | 0.11 % | $ 172 M |  Israel |
 |
Summit Therapeutics
SMMT
|
-57.38 | $ 17.78 | -0.34 % | $ 13.3 B |  Britain |
 |
Checkpoint Therapeutics
CKPT
|
444.94 | - | - | $ 169 M | USA |
 |
Syndax Pharmaceuticals
SNDX
|
-66.67 | $ 9.43 | -0.89 % | $ 817 M | USA |
 |
Spero Therapeutics
SPRO
|
10.7 | $ 1.01 | -5.61 % | $ 56.6 M | USA |
 |
Sarepta Therapeutics
SRPT
|
-31.04 | $ 16.4 | -5.54 % | $ 1.64 B | USA |
 |
Tarsus Pharmaceuticals
TARS
|
-16.64 | $ 73.9 | 4.32 % | $ 3.09 B | USA |
 |
Bio-Techne Corporation
TECH
|
11.95 | $ 72.83 | -0.01 % | $ 11.4 B | USA |
 |
Sage Therapeutics
SAGE
|
-92.97 | - | - | $ 527 M | USA |
 |
Taro Pharmaceutical Industries Ltd.
TARO
|
1.01 | - | - | $ 1.62 B | Israel |
 |
Cabaletta Bio
CABA
|
-149.87 | $ 1.43 | -5.0 % | $ 144 M | USA |
 |
Forma Therapeutics Holdings
FMTX
|
-34.91 | - | - | $ 958 M | USA |
 |
Blueprint Medicines Corporation
BPMC
|
-60.1 | - | - | $ 8.14 B | USA |
 |
Horizon Therapeutics Public Limited Company
HZNP
|
7.56 | - | - | $ 26.6 B |  Irlanda |
 |
Tonix Pharmaceuticals Holding Corp.
TNXP
|
-51.03 | $ 4.12 | -8.35 % | $ 35.1 M | USA |
 |
Paratek Pharmaceuticals
PRTK
|
27.02 | - | - | $ 121 M | USA |
 |
DBV Technologies S.A.
DBVT
|
-83.7 | $ 11.55 | 4.52 % | $ 1.61 B |  France |
 |
Gilead Sciences
GILD
|
44.14 | $ 170.68 | 0.8 % | $ 212 B | USA |
 |
Taysha Gene Therapies
TSHA
|
-44.75 | $ 4.28 | -2.06 % | $ 1.37 B | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
-379.93 | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Adverum Biotechnologies
ADVM
|
-196.79 | - | - | $ 86.2 M | USA |
 |
Unity Biotechnology
UBX
|
-480.0 | - | -33.41 % | $ 3.37 M | USA |
 |
iTeos Therapeutics
ITOS
|
-27.03 | - | - | $ 411 M | USA |
 |
Gossamer Bio
GOSS
|
-156.9 | $ 11.2 | 5.21 % | $ 2.56 B | USA |
 |
GeoVax Labs
GOVX
|
-565.71 | $ 0.11 | -22.17 % | $ 105 K | USA |
 |
United Therapeutics Corporation
UTHR
|
20.39 | $ 588.33 | 1.01 % | $ 26.1 B | USA |
 |
Seelos Therapeutics
SEEL
|
120.86 | - | -47.76 % | $ 6.27 M | USA |
 |
Vericel Corporation
VCEL
|
2.52 | $ 59.02 | 1.08 % | $ 2.97 B | USA |
 |
Veracyte
VCYT
|
4.29 | $ 24.05 | -7.21 % | $ 1.89 B | USA |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
GlaxoSmithKline plc
GSK
|
19.97 | $ 51.25 | -0.56 % | $ 208 B | Britain |
 |
Vir Biotechnology
VIR
|
-52.67 | $ 13.17 | -3.48 % | $ 1.82 B | USA |
 |
Viking Therapeutics
VKTX
|
-61.55 | $ 28.67 | -1.1 % | $ 3.23 B | USA |
 |
Vanda Pharmaceuticals
VNDA
|
-43.97 | $ 4.07 | -0.49 % | $ 240 M | USA |
 |
Verrica Pharmaceuticals
VRCA
|
-49.25 | $ 3.55 | -1.11 % | $ 37.8 M | USA |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
19.16 | $ 547.74 | -0.57 % | $ 140 B | USA |
 |
Kiromic BioPharma
KRBP
|
188.88 | - | 6.61 % | $ 3.08 M | USA |
 |
vTv Therapeutics
VTVT
|
-39.41 | $ 20.88 | -1.42 % | $ 83.8 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
-353.49 | $ 3.81 | -3.3 % | $ 1.69 M | USA |
 |
Voyager Therapeutics
VYGR
|
-58.41 | $ 1.82 | -8.54 % | $ 107 M | USA |
 |
Calithera Biosciences
CALA
|
-206.33 | - | -10.95 % | $ 876 K | USA |
 |
Applied Molecular Transport
AMTI
|
-209.11 | - | - | $ 10.1 M | USA |
 |
Wave Life Sciences Ltd.
WVE
|
-40.22 | $ 3.41 | -2.01 % | $ 575 M | Singapore |